BRKR

Bruker Corp (BRKR) | Rumor.io

Bruker

BRKR

Attention (50-day avg)0%

Attention rank (50-day avg)#1,501

Bullish sentiment (50-day avg)84%

Price to earnings ratio74.9

Market capitalization9.6B

Earnings per share-0.75

Dividend yield (TTM)0.32%

Revenue (annual)3.4B

Net income (annual)-8.3M

Social

What share of all stock conversation is about BRKR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% +0

Aug 4

Bruker Corporation's (BRKR) second-quarter 2026 revenue came in at $838.5M, beating expectations and increasing 5.2% year-over-year.
The company's management cut full-year revenue guidance to $3.56B from $3.59B, despite adjusted EPS beating estimates at $0.49 versus $0.38 expected.
Bruker's Q2 results were overshadowed by valuation concerns, leading to a 20.2% decline in stock price on the day, with the market ignoring the company's adjusted EPS beat.

Generated by AI

Sentiment

Of the messages about BRKR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% 0	100% +29.03	83.86% +72.91
Bearish	—	0% 0	0% -29.03	16.14% -72.91

Bullish· May 12

BidaskClub has upgraded Bruker Corporation's stock rating, indicating increased optimism about the company's prospects.
This upgrade suggests that analysts believe Bruker Corporation has the potential for growth and improvement in its financial performance.
The upgraded rating may lead to increased investor confidence and potentially drive up the stock price.

Bearish· Apr 5

Bruker Corporation's stock price may decline further due to the downgrades from multiple top-tier analysts, including BofA/Merrill Lynch and Bank of America.
The company's recent downgrades may be a result of a decrease in investor confidence, as evidenced by the downgrade from Leerink Swann, which ranked Bruker 71st out of 120 stocks in its report.
Bruker's stock price may be overvalued, as suggested by the downgrade from Bank of America, which increased its price target to $27, implying a potential decrease in value.

Generated by AI

Topics

Of the messages about BRKR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	53.33%	89.41%	3.68%
Announcements	—	46.67%	10%	3.34%
Earnings	—	0%	0%	0.15%
Analysts	—	0%	0.59%	46.34%
Controversies	—	0%	0%	0.04%
Macro	—	0%	0%	46.46%

Earnings· Nov 1

BRKR reported FQ3 earnings of 37c EPS and $466.60M in revenue.
BRKR beat the Estimize EPS consensus by 5c and the Estimize Revenue consensus by $10.13M.
BRKR reported earnings of $0.37, exceeding the consensus estimate of $0.30.

Announcements· Jun 6

Bruker Corporation (BRKR) launches timsTOF HT with greater dynamic range for enhancing unbiased, high-confidence 4D proteomics.
Bruker introduces novel point-of-need applied mass spectrometry tools for accelerated measurements without chromatography, including the DART-EVOQ triple quadrupole mass spectrometer.
Bruker announces key innovations for highly multiplexed spatial proteomics and multiomic tissue imaging at large field-of-view, including enhancements for MALDI HiPLEX-IHC mass spectrometry imaging.

Generated by AI

Community

Of the messages about BRKR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	67.39%	64.89%	6.8%
Newcomers	0%	32.61%	35.11%	93.2%

Regulars· Feb 11

Bruker Corporation reported Q4 sales of $683.5M, a 8.9% YoY increase, and EPS of $0.59, meeting expectations.
The company issued FY22 guidance, predicting 5-7% sales growth and EPS of $2.29 to $2.33.
Bruker's Q4 results show a strong organic growth, with a 11% increase in sales compared to the same period last year.

Newcomers· Nov 3

Newcomers are focused on Bruker Corporation's Q3 2025 results, where the company reported an adjusted EPS of $0.45, beating expectations despite a revenue decline.
The Q3 revenue of $860.5M fell short of consensus, leading Bruker to cut its FY25 EPS view to $1.85-$1.90 and its revenue view to $3.41B-$3.44B.
The company's guidance cut and revenue miss have triggered a spike in volatility, with traders eyeing the January earnings report and considering a flush and rebound play, with key watch points at $36.40 support and $40 cap.

Generated by AI

Bruker (NASDAQ:BRKR) CFO Gerald Herman said the company’s second-quarter results reflected stronger-than-expected organic order bookings and earnings per share, while revenue came in later than anticipated. He attributed the revenue timing primarily to a mixed demand environment and shipment timing,

3d agoYahoo Finance

Bruker at Bank of America Global Healthcare Conference: growth mix lifts outlook

8d agoInvesting.com

Also Discussed

Investors talking about BRKR also mention

#	Name	Attention
1	Fortrea Holdings Inc.FTRE	0%0
2	Vestis CorporationVSTS	0%new
3	Dianthus Therapeutics Inc.DNTH	0%0
4	ASGN Inc.ASGN	0%0
5	Integra LifeSciences Holdings CorporationIART	0%0
6	PDCO - Patterson Companies, Inc.	——
7	Teleflex IncorporatedTFX	0%+0
8	Insight Enterprises, Inc.NSIT	0%0
9	Molina Healthcare Inc.MOH	0%new
10	Acadia Healthcare Company, Inc.ACHC	0%new

Bruker Corp

Healthcare
Medical Devices

Bruker Corp. is a scientific instruments and analytical solutions company that provides technologies for life science, materials research, and diagnostic applications. The company develops, manufactures, and distributes high-performance tools used to study matter at microscopic, molecular, and cellular levels, supporting research and testing across academic, clinical, industrial, and government settings. Its product portfolio includes magnetic resonance, mass spectrometry, X-ray, microscopy, metrology, chromatography, and molecular spectroscopy systems, along with specialized diagnostic and microbiology solutions. Bruker serves customers in biopharmaceuticals, in-vitro diagnostics, nanotechnology, semiconductor process control, and applied markets, making it an important supplier of advanced measurement and detection technologies in the global scientific equipment market.

Website

Location

40 Manning Road

Billerica, MA, 01821

United States

Social

What share of all stock conversation is about BRKR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% +0

Aug 4

Bruker Corporation's (BRKR) second-quarter 2026 revenue came in at $838.5M, beating expectations and increasing 5.2% year-over-year.
The company's management cut full-year revenue guidance to $3.56B from $3.59B, despite adjusted EPS beating estimates at $0.49 versus $0.38 expected.
Bruker's Q2 results were overshadowed by valuation concerns, leading to a 20.2% decline in stock price on the day, with the market ignoring the company's adjusted EPS beat.

Generated by AI

Sentiment

Of the messages about BRKR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% 0	100% +29.03	83.86% +72.91
Bearish	—	0% 0	0% -29.03	16.14% -72.91

Bullish· May 12

BidaskClub has upgraded Bruker Corporation's stock rating, indicating increased optimism about the company's prospects.
This upgrade suggests that analysts believe Bruker Corporation has the potential for growth and improvement in its financial performance.
The upgraded rating may lead to increased investor confidence and potentially drive up the stock price.

Bearish· Apr 5

Bruker Corporation's stock price may decline further due to the downgrades from multiple top-tier analysts, including BofA/Merrill Lynch and Bank of America.
The company's recent downgrades may be a result of a decrease in investor confidence, as evidenced by the downgrade from Leerink Swann, which ranked Bruker 71st out of 120 stocks in its report.
Bruker's stock price may be overvalued, as suggested by the downgrade from Bank of America, which increased its price target to $27, implying a potential decrease in value.

Generated by AI

Topics

Of the messages about BRKR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	53.33%	89.41%	3.68%
Announcements	—	46.67%	10%	3.34%
Earnings	—	0%	0%	0.15%
Analysts	—	0%	0.59%	46.34%
Controversies	—	0%	0%	0.04%
Macro	—	0%	0%	46.46%

Earnings· Nov 1

BRKR reported FQ3 earnings of 37c EPS and $466.60M in revenue.
BRKR beat the Estimize EPS consensus by 5c and the Estimize Revenue consensus by $10.13M.
BRKR reported earnings of $0.37, exceeding the consensus estimate of $0.30.

Announcements· Jun 6

Bruker Corporation (BRKR) launches timsTOF HT with greater dynamic range for enhancing unbiased, high-confidence 4D proteomics.
Bruker introduces novel point-of-need applied mass spectrometry tools for accelerated measurements without chromatography, including the DART-EVOQ triple quadrupole mass spectrometer.
Bruker announces key innovations for highly multiplexed spatial proteomics and multiomic tissue imaging at large field-of-view, including enhancements for MALDI HiPLEX-IHC mass spectrometry imaging.

Generated by AI

Community

Of the messages about BRKR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	67.39%	64.89%	6.8%
Newcomers	0%	32.61%	35.11%	93.2%

Regulars· Feb 11

Bruker Corporation reported Q4 sales of $683.5M, a 8.9% YoY increase, and EPS of $0.59, meeting expectations.
The company issued FY22 guidance, predicting 5-7% sales growth and EPS of $2.29 to $2.33.
Bruker's Q4 results show a strong organic growth, with a 11% increase in sales compared to the same period last year.

Newcomers· Nov 3

Newcomers are focused on Bruker Corporation's Q3 2025 results, where the company reported an adjusted EPS of $0.45, beating expectations despite a revenue decline.
The Q3 revenue of $860.5M fell short of consensus, leading Bruker to cut its FY25 EPS view to $1.85-$1.90 and its revenue view to $3.41B-$3.44B.
The company's guidance cut and revenue miss have triggered a spike in volatility, with traders eyeing the January earnings report and considering a flush and rebound play, with key watch points at $36.40 support and $40 cap.

Generated by AI

Bruker

Social

Aug 4

Bullish· May 12

Bearish· Apr 5

Earnings· Nov 1

Announcements· Jun 6

Regulars· Feb 11

Newcomers· Nov 3

Bruker unveils proteomics workflows at HUPO congress

Bruker Sees AI-Fueled Semiconductor Demand, Targets Critical Q4 Revenue Rebound

Bruker at Bank of America Global Healthcare Conference: growth mix lifts outlook

Is Bruker (BRKR) Using Flagship Academic NMR Deals To Deepen Its High-End Moat?

Bruker Gets More Than $6 Million Order From University of California, Berkeley

UC Berkeley orders NMR equipment from Bruker for over $6M

Also Discussed

Bruker Corp

Company Information

Location

Bruker unveils proteomics workflows at HUPO congress

Bruker Sees AI-Fueled Semiconductor Demand, Targets Critical Q4 Revenue Rebound

Bruker at Bank of America Global Healthcare Conference: growth mix lifts outlook

Is Bruker (BRKR) Using Flagship Academic NMR Deals To Deepen Its High-End Moat?

Bruker Gets More Than $6 Million Order From University of California, Berkeley

UC Berkeley orders NMR equipment from Bruker for over $6M

Also Discussed

Social

Aug 4

Bullish· May 12

Bearish· Apr 5

Earnings· Nov 1

Announcements· Jun 6

Regulars· Feb 11

Newcomers· Nov 3